
As healthcare costs continue to rise, accurate cost-effectiveness estimates are crucial. However, estimating the costs and outcomes of different interventions is complicated by uncertainty.
In model-based health economic evaluations (HEEs), uncertainty can arise from limited data, methodological limitations, and variability in clinical outcomes.
A recent review identified 80 methods for identifying, analyzing, and communicating uncertainty in HEEs. Quantifying uncertainty wherever possible is crucial to ensure accurate and unbiased cost-effectiveness estimates, ultimately leading to optimal allocation of healthcare resources
Recent Posts
Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management
Advancements in CGM for Type 2 Diabetes Management
A recent JAMA Insights article, explores the integration of continuous glucose monitoring as a complementary tool to traditional hemoglobin A1c (HbA1c) an...
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia
NICE Backs Obecabtagene Autoleucel
The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-developed chimeric antigen receptor (CAR) T-cell trea...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before Phase 3
Early HEOR Market Access Integration
In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must occur earlier in drug development—ideally before Ph...